ECP and solid organ transplantation.

Area of Science:

• Photomedicine
• Immunology
• Dermatology

Background:

• Extracorporeal photopheresis (ECP) has been utilized since 1983.
• Established as a safe and effective treatment for cutaneous T-cell lymphoma (CTCL), particularly Sezary syndrome.
• Proven efficacy in managing T-cell-mediated diseases, including graft-vs.-host disease (GVHD).

Purpose of the Study:

• To review the established and emerging applications of ECP.
• To explore ECP's role in managing allograft rejection and in calcineurin inhibitor (CNI)-sparing protocols.
• To discuss the proposed mechanisms of ECP's efficacy.

Main Methods:

• Literature review of ECP applications in photomedicine.
• Analysis of studies documenting ECP's effectiveness in various T-cell-mediated diseases and transplant settings.
• Examination of proposed mechanisms, including lymphocyte apoptosis and regulatory T-cell induction.

Main Results:

• ECP is a well-established palliative treatment for CTCL and Sezary syndrome.
• ECP effectively treats and prevents acute and chronic GVHD.
• Recent studies demonstrate ECP's success in managing heart and lung allograft rejection without increased infections.
• ECP is utilized in CNI-sparing protocols, potentially through lymphocyte apoptosis and Treg induction.

Conclusions:

• ECP is a versatile therapeutic option for T-cell-mediated conditions.
• ECP offers a non-immunosuppressive approach for managing transplant rejection and potentially reducing CNI use.
• Further research is needed to finalize the exact indications for ECP in specific clinical frameworks.